H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Aura Biosciences Inc today and set a price target of $22.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Aura Biosciences Inc’s promising advancements in their clinical programs. The company’s Phase 3 CoMpass trial for early choroidal melanoma is progressing well, with full enrollment expected by year-end, supported by strong global engagement. This trial’s design, which uses tumor growth as an enrichment criterion, aims to improve the likelihood of achieving progression-free survival endpoints by focusing on patients with active disease biology.
In addition, Aura’s expansion of the metastases-to-the-choroid program to include all solid tumors, backed by preclinical evidence, demonstrates the versatility of their bel-sar platform. The NMIBC program’s exploration of immune-ablative and multimodal neoadjuvant approaches further showcases bel-sar’s potential in inducing targeted tumor destruction and local immune activation. Recent intellectual property developments, including a new formulation patent, enhance Aura’s competitive positioning, reinforcing the Buy rating and the $22 price target.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as Merus, I-MAB, and ImmunityBio. According to TipRanks, Y. Maldonado has an average return of 1.6% and a 37.01% success rate on recommended stocks.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $23.00 price target.